Shares of X4 Pharmaceuticals, Inc. (NASDAQ: XFOR - Get Free Report) have been given an average recom

X4 Pharmaceuticals (XFOR) is technically in oversold territory now, so the heavy selling pressure mi

BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on i

- FDA Agrees to Reduced Sample Size for the Global 4WARD Phase 3 Chronic Neutropenia Trial - - Expec

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on i

X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which

Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% a

X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.13) per share which beat the analy

BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on im

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on im

Wells Fargo analyst Derek Archila initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a O

BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on im

BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on im

Leerink Partners analyst Thomas Smith initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on im

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on imp

X4 Pharmaceuticals (XFOR) witnesses a hammer chart pattern, indicating support found by the stock af

X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which

X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0.16 per share versus the Zacks Consens

X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.16) per share which beat the analy

- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 20

- European Commercialization will be Led by X4 Pharmaceuticals' Partner, Norgine - - Global, Piv

- European Commercialization will be Led by X4 Pharmaceuticals' Partner, Norgine -  - Global, Pivota

BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on i

X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0.22 per share versus the Zacks Consens

X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.22) per share which beat the analy

- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 - - Posi

Guggenheim analyst Michael Schmidt initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a

Stifel analyst James Condulis maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises th

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR)

X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.69) per share which beat the analy

And, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 700,000 sha

X4 Pharmaceuticals (NASDAQ:XFOR) ("X4" or the "Company"), a company driven to improv

Organizational restructuring including a 50% reduction in workforce that is anticipated to result in

Stifel analyst Stephen Willey maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers th

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR)

$60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise